RANI vs CDTX

Analysts rate Rani Therapeutics Holdings, Inc.

(RANI) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cidara Therapeutics, Inc.

(CDTX) delivered a total return of +450. 7%, compared to -91. 5% for Rani Therapeutics Holdings, Inc. (RANI). Over 10 years, the gap is even starker: CDTX returned -16. 0% versus RANI's -91. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cidara Therapeutics, Inc.

(CDTX) is the lower-risk stock at 0. 82β versus Rani Therapeutics Holdings, Inc. 's 2. 38β — meaning RANI is approximately 190% more volatile than CDTX relative to the S&P 500. On balance sheet safety, Cidara Therapeutics, Inc. (CDTX) carries a lower debt/equity ratio of 2% versus 9% for Rani Therapeutics Holdings, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Rani Therapeutics Holdings, Inc.

grew EPS 21. 1% year-over-year, compared to -409. 5% for Cidara Therapeutics, Inc.. Over a 3-year CAGR, RANI leads at -27. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Rani Therapeutics Holdings, Inc.

(RANI) is the more profitable company, earning -29. 2% net margin versus -133. 2% for Cidara Therapeutics, Inc. — meaning it keeps -29. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RANI leads at -51. 9% versus -138. 1% for CDTX. At the gross margin level — before operating expenses — RANI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cidara Therapeutics, Inc.

(CDTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 82)). Rani Therapeutics Holdings, Inc. (RANI) carries a higher beta of 2. 38 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CDTX: -16. 0%, RANI: -91. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.